# A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

Study · id `cardio:ct-nct04505098` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04505098](<https://clinicaltrials.gov/study/NCT04505098>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04505098

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 39600 participants.

## Technical summary

Registry record NCT04505098. Randomized; single masking; primary purpose prevention. Start 2020-08-07 (actual); primary completion 2022-12-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 39600 participants (enrolled count; ClinicalTrials.gov record NCT04505098, source copy `cardio:ctgov-nct04505098-2023-07-18`, retrieved 2026-10-31)
- Started: 2020-08-07 (actual) (ClinicalTrials.gov record NCT04505098, source copy `cardio:ctgov-nct04505098-2023-07-18`, retrieved 2026-10-31)
- Primary completion: 2022-12-15 (actual) (ClinicalTrials.gov record NCT04505098, source copy `cardio:ctgov-nct04505098-2023-07-18`, retrieved 2026-10-31)
- Completion: 2022-12-15 (actual) (ClinicalTrials.gov record NCT04505098, source copy `cardio:ctgov-nct04505098-2023-07-18`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT04505098, source copy `cardio:ctgov-nct04505098-2023-07-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04505098-2023-07-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
- Acronym: MITIGATE
- Condition: Covid19
- Condition: Atherosclerosis
- Condition: Cardiovascular Diseases
- Condition: Upper Respiratory Tract Infections
- Intervention (Drug): Icosapent ethyl
- Lead sponsor: Kaiser Permanente
- Lead sponsor class: OTHER
- Collaborator: Amarin Corporation
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry intervention name matches this record: Icosapent ethyl (`cardio:icosapent-ethyl`)
- Registry lists this organization as the lead sponsor: Kaiser Permanente (`cardio:org-kaiser-permanente`)

## Provenance

Content hash: 22d1c9746bd1f1c781aadbd5ae3fd6c10b49952e6129a3724f9f999c1e40097c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
